...
imux-img

Immunic Inc, Common Stock

IMUX

NSQ

$1.21

-$0.03

(-2.42%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$118.90M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
653.06K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.88
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.97 L
$2.11 H
$1.21

About Immunic Inc, Common Stock

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameIMUXSectorS&P500
1-Week Return-3.2%-1.8%-0.77%
1-Month Return-1.63%-3.48%0.71%
3-Month Return-20.39%-7.2%8.81%
6-Month Return-4.72%-1.54%12.32%
1-Year Return2.54%8.39%30.57%
3-Year Return-86.83%6.07%29.21%
5-Year Return-86.28%44.07%91.95%
10-Year Return-99.85%106.3%196.04%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue50.00K39.00K85.00K77.00K111.00K[{"date":"2019-12-31","value":45.05,"profit":true},{"date":"2020-12-31","value":35.14,"profit":true},{"date":"2021-12-31","value":76.58,"profit":true},{"date":"2022-12-31","value":69.37,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(50.00K)(39.00K)(85.00K)(77.00K)(111.00K)[{"date":"2019-12-31","value":-5000000,"profit":false},{"date":"2020-12-31","value":-3900000,"profit":false},{"date":"2021-12-31","value":-8500000,"profit":false},{"date":"2022-12-31","value":-7700000,"profit":false},{"date":"2023-12-31","value":-11100000,"profit":false}]
Gross Margin-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses37.03M48.97M91.67M86.52M99.22M[{"date":"2019-12-31","value":37.32,"profit":true},{"date":"2020-12-31","value":49.35,"profit":true},{"date":"2021-12-31","value":92.38,"profit":true},{"date":"2022-12-31","value":87.2,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(37.03M)(48.97M)(91.67M)(119.49M)(99.22M)[{"date":"2019-12-31","value":-3703200000,"profit":false},{"date":"2020-12-31","value":-4897100000,"profit":false},{"date":"2021-12-31","value":-9166500000,"profit":false},{"date":"2022-12-31","value":-11948800000,"profit":false},{"date":"2023-12-31","value":-9922300000,"profit":false}]
Total Non-Operating Income/Expense2.21M5.01M(1.21M)122.00K8.69M[{"date":"2019-12-31","value":25.4,"profit":true},{"date":"2020-12-31","value":57.7,"profit":true},{"date":"2021-12-31","value":-13.98,"profit":false},{"date":"2022-12-31","value":1.4,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(34.93M)(44.02M)(92.94M)(120.41M)(93.61M)[{"date":"2019-12-31","value":-3493300000,"profit":false},{"date":"2020-12-31","value":-4401700000,"profit":false},{"date":"2021-12-31","value":-9294500000,"profit":false},{"date":"2022-12-31","value":-12040700000,"profit":false},{"date":"2023-12-31","value":-9361200000,"profit":false}]
Income Taxes(107.00K)(58.00K)(151.00K)33.89M-[{"date":"2019-12-31","value":-0.32,"profit":false},{"date":"2020-12-31","value":-0.17,"profit":false},{"date":"2021-12-31","value":-0.45,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes(34.83M)(43.96M)(92.79M)(154.30M)-[{"date":"2019-12-31","value":-3482600000,"profit":false},{"date":"2020-12-31","value":-4395900000,"profit":false},{"date":"2021-12-31","value":-9279400000,"profit":false},{"date":"2022-12-31","value":-15429600000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(34.93M)(44.02M)(92.94M)(120.41M)(93.61M)[{"date":"2019-12-31","value":-3493300000,"profit":false},{"date":"2020-12-31","value":-4401700000,"profit":false},{"date":"2021-12-31","value":-9294500000,"profit":false},{"date":"2022-12-31","value":-12040700000,"profit":false},{"date":"2023-12-31","value":-9361200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(34.83M)(43.96M)(92.79M)(154.30M)(93.61M)[{"date":"2019-12-31","value":-3482600000,"profit":false},{"date":"2020-12-31","value":-4395900000,"profit":false},{"date":"2021-12-31","value":-9279400000,"profit":false},{"date":"2022-12-31","value":-15429600000,"profit":false},{"date":"2023-12-31","value":-9361200000,"profit":false}]
EPS (Diluted)(3.81)(2.85)(3.93)(3.77)(2.11)[{"date":"2019-12-31","value":-380.5,"profit":false},{"date":"2020-12-31","value":-285,"profit":false},{"date":"2021-12-31","value":-393,"profit":false},{"date":"2022-12-31","value":-377,"profit":false},{"date":"2023-12-31","value":-211,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

IMUX
Cash Ratio 2.53
Current Ratio 2.71

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

IMUX
ROA (LTM) -90.90%
ROE (LTM) -216.24%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

IMUX
Debt Ratio Lower is generally better. Negative is bad. 0.36
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.64

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

IMUX
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 2.80
Price/FCF NM
EV/R 0.00
EV/Ebitda 0.21

FAQs

What is Immunic Inc share price today?

Immunic Inc (IMUX) share price today is $1.21

Can Indians buy Immunic Inc shares?

Yes, Indians can buy shares of Immunic Inc (IMUX) on Vested. To buy Immunic Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IMUX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Immunic Inc be purchased?

Yes, you can purchase fractional shares of Immunic Inc (IMUX) via the Vested app. You can start investing in Immunic Inc (IMUX) with a minimum investment of $1.

How to invest in Immunic Inc shares from India?

You can invest in shares of Immunic Inc (IMUX) via Vested in three simple steps:

  • Click on Sign Up or Invest in IMUX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Immunic Inc shares
What is Immunic Inc 52-week high and low stock price?

The 52-week high price of Immunic Inc (IMUX) is $2.11. The 52-week low price of Immunic Inc (IMUX) is $0.97.

What is Immunic Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Immunic Inc (IMUX) is

What is Immunic Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Immunic Inc (IMUX) is 2.80

What is Immunic Inc dividend yield?

The dividend yield of Immunic Inc (IMUX) is 0.00%

What is the Market Cap of Immunic Inc?

The market capitalization of Immunic Inc (IMUX) is $118.90M

What is Immunic Inc’s stock symbol?

The stock symbol (or ticker) of Immunic Inc is IMUX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top